Cue Price To Sales Ratio vs Book Value Per Share Analysis

CUE Stock

USD 1.04 0.04 3.70%

Cue Biopharma financial indicator trend analysis is way more than just evaluating Cue Biopharma prevailing accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Cue Biopharma is a good investment. Please check the relationship between Cue Biopharma Price To Sales Ratio and its Book Value Per Share accounts. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.

Price To Sales Ratio vs Book Value Per Share

Price To Sales Ratio vs Book Value Per Share Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Cue Biopharma Price To Sales Ratio account and Book Value Per Share. At this time, the significance of the direction appears to have no relationship.

The correlation between Cue Biopharma's Price To Sales Ratio and Book Value Per Share is 0.09. Overlapping area represents the amount of variation of Price To Sales Ratio that can explain the historical movement of Book Value Per Share in the same time period over historical financial statements of Cue Biopharma, assuming nothing else is changed. The correlation between historical values of Cue Biopharma's Price To Sales Ratio and Book Value Per Share is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Price To Sales Ratio of Cue Biopharma are associated (or correlated) with its Book Value Per Share. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Book Value Per Share has no effect on the direction of Price To Sales Ratio i.e., Cue Biopharma's Price To Sales Ratio and Book Value Per Share go up and down completely randomly.

Correlation Coefficient

0.09

Relationship Direction	Positive
Relationship Strength	Insignificant

View All Relationships

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Cue Biopharma stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Cue Biopharma sales, a figure that is much harder to manipulate than other Cue Biopharma multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Most indicators from Cue Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Cue Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.The current year's Issuance Of Capital Stock is expected to grow to about 24 M, whereas Selling General Administrative is forecasted to decline to about 11.7 M.

	2021	2022	2023	2024 (projected)
Interest Income	45.9K	928.2K	2.7M	2.8M
Net Interest Income	45.9K	214.4K	1.4M	1.5M

Interest Income Net Interest Income

Cue Biopharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Common Stock Total Equity	Common Stock Shares Outstanding	Short Term Investments	Non Current Liabilities Total	Other Current Assets	Other Stockholder Equity	Total Liab	Deferred Long Term Liab	Property Plant And Equipment Gross	Total Current Assets	Common Stock
Total Assets		0.28	0.91	0.99	0.66	0.97	0.9	-0.91	-0.78	0.83	0.96	0.91	0.87	0.86	0.99	0.86	0.61	0.54	0.76	0.91	0.89	0.91	0.82	0.85	1.0	0.88
Other Current Liab	0.28		0.36	0.19	0.37	0.34	0.3	-0.02	-0.66	0.52	0.17	0.34	0.42	0.46	0.24	0.56	0.55	0.28	0.61	0.16	0.5	0.49	0.38	0.39	0.26	0.58
Total Current Liabilities	0.91	0.36		0.86	0.54	0.95	0.9	-0.8	-0.88	0.9	0.88	0.92	0.93	0.96	0.88	0.94	0.8	0.42	0.76	0.9	0.95	0.96	0.75	0.87	0.9	0.94
Total Stockholder Equity	0.99	0.19	0.86		0.68	0.94	0.85	-0.95	-0.7	0.76	0.97	0.85	0.8	0.77	0.98	0.78	0.51	0.49	0.67	0.87	0.81	0.83	0.82	0.78	0.99	0.8
Other Liab	0.66	0.37	0.54	0.68		0.66	0.38	-0.66	-0.38	0.55	0.63	0.42	0.51	0.5	0.66	0.51	0.16	0.5	0.41	0.49	0.47	0.52	0.93	0.32	0.69	0.52
Net Tangible Assets	0.97	0.34	0.95	0.94	0.66		0.86	-0.91	-0.82	0.89	0.97	0.87	0.84	0.87	0.96	0.92	0.73	0.41	0.72	0.86	0.92	0.92	0.84	0.83	0.97	0.92
Property Plant And Equipment Net	0.9	0.3	0.9	0.85	0.38	0.86		-0.72	-0.85	0.82	0.82	1.0	0.93	0.91	0.85	0.87	0.73	0.48	0.83	0.89	0.93	0.93	0.6	0.98	0.86	0.88
Net Debt	-0.91	-0.02	-0.8	-0.95	-0.66	-0.91	-0.72		0.57	-0.68	-0.98	-0.72	-0.64	-0.64	-0.92	-0.67	-0.44	-0.25	-0.43	-0.78	-0.71	-0.7	-0.79	-0.65	-0.93	-0.69
Retained Earnings	-0.78	-0.66	-0.88	-0.7	-0.38	-0.82	-0.85	0.57		-0.9	-0.72	-0.86	-0.83	-0.87	-0.75	-0.92	-0.9	-0.32	-0.83	-0.77	-0.94	-0.91	-0.59	-0.88	-0.75	-0.94
Accounts Payable	0.83	0.52	0.9	0.76	0.55	0.89	0.82	-0.68	-0.9		0.78	0.83	0.81	0.87	0.83	0.95	0.86	0.41	0.82	0.84	0.95	0.92	0.79	0.86	0.81	0.96
Cash	0.96	0.17	0.88	0.97	0.63	0.97	0.82	-0.98	-0.72	0.78		0.82	0.74	0.75	0.97	0.8	0.59	0.31	0.59	0.83	0.83	0.81	0.79	0.77	0.97	0.81
Non Current Assets Total	0.91	0.34	0.92	0.85	0.42	0.87	1.0	-0.72	-0.86	0.83	0.82		0.96	0.95	0.85	0.88	0.74	0.53	0.85	0.9	0.94	0.95	0.64	0.97	0.87	0.9
Non Currrent Assets Other	0.87	0.42	0.93	0.8	0.51	0.84	0.93	-0.64	-0.83	0.81	0.74	0.96		0.99	0.79	0.88	0.69	0.64	0.86	0.88	0.9	0.96	0.68	0.89	0.84	0.89
Other Assets	0.86	0.46	0.96	0.77	0.5	0.87	0.91	-0.64	-0.87	0.87	0.75	0.95	0.99		0.79	0.93	0.78	0.57	0.86	0.87	0.94	0.98	0.7	0.9	0.82	0.93
Cash And Short Term Investments	0.99	0.24	0.88	0.98	0.66	0.96	0.85	-0.92	-0.75	0.83	0.97	0.85	0.79	0.79		0.83	0.6	0.51	0.72	0.9	0.86	0.87	0.83	0.81	0.99	0.85
Common Stock Total Equity	0.86	0.56	0.94	0.78	0.51	0.92	0.87	-0.67	-0.92	0.95	0.8	0.88	0.88	0.93	0.83		0.9	0.47	0.88	0.81	0.99	0.97	0.74	0.9	0.84	1.0
Common Stock Shares Outstanding	0.61	0.55	0.8	0.51	0.16	0.73	0.73	-0.44	-0.9	0.86	0.59	0.74	0.69	0.78	0.6	0.9		0.17	0.74	0.63	0.9	0.83	0.45	0.81	0.58	0.89
Short Term Investments	0.54	0.28	0.42	0.49	0.5	0.41	0.48	-0.25	-0.32	0.41	0.31	0.53	0.64	0.57	0.51	0.47	0.17		0.75	0.54	0.45	0.58	0.52	0.44	0.53	0.47
Non Current Liabilities Total	0.76	0.61	0.76	0.67	0.41	0.72	0.83	-0.43	-0.83	0.82	0.59	0.85	0.86	0.86	0.72	0.88	0.74	0.75		0.75	0.88	0.91	0.6	0.86	0.72	0.89
Other Current Assets	0.91	0.16	0.9	0.87	0.49	0.86	0.89	-0.78	-0.77	0.84	0.83	0.9	0.88	0.87	0.9	0.81	0.63	0.54	0.75		0.86	0.89	0.71	0.84	0.89	0.82
Other Stockholder Equity	0.89	0.5	0.95	0.81	0.47	0.92	0.93	-0.71	-0.94	0.95	0.83	0.94	0.9	0.94	0.86	0.99	0.9	0.45	0.88	0.86		0.98	0.71	0.95	0.86	0.99
Total Liab	0.91	0.49	0.96	0.83	0.52	0.92	0.93	-0.7	-0.91	0.92	0.81	0.95	0.96	0.98	0.87	0.97	0.83	0.58	0.91	0.89	0.98		0.73	0.92	0.88	0.98
Deferred Long Term Liab	0.82	0.38	0.75	0.82	0.93	0.84	0.6	-0.79	-0.59	0.79	0.79	0.64	0.68	0.7	0.83	0.74	0.45	0.52	0.6	0.71	0.71	0.73		0.57	0.84	0.75
Property Plant And Equipment Gross	0.85	0.39	0.87	0.78	0.32	0.83	0.98	-0.65	-0.88	0.86	0.77	0.97	0.89	0.9	0.81	0.9	0.81	0.44	0.86	0.84	0.95	0.92	0.57		0.81	0.91
Total Current Assets	1.0	0.26	0.9	0.99	0.69	0.97	0.86	-0.93	-0.75	0.81	0.97	0.87	0.84	0.82	0.99	0.84	0.58	0.53	0.72	0.89	0.86	0.88	0.84	0.81		0.85
Common Stock	0.88	0.58	0.94	0.8	0.52	0.92	0.88	-0.69	-0.94	0.96	0.81	0.9	0.89	0.93	0.85	1.0	0.89	0.47	0.89	0.82	0.99	0.98	0.75	0.91	0.85

Click cells to compare fundamentals

Cue Biopharma Account Relationship Matchups

Cue Biopharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	71.6M	99.5M	83.4M	91.3M	61.5M	66.4M
Other Current Liab	2.2M	(2.0M)	333.6K	3.6M	4.1M	4.3M
Total Current Liabilities	11.7M	16.3M	12.8M	11.5M	17.1M	10.1M
Total Stockholder Equity	54.6M	78.9M	65.5M	65.7M	37.1M	51.3M
Net Tangible Assets	54.6M	78.9M	65.5M	65.7M	75.5M	52.6M
Property Plant And Equipment Net	7.2M	8.9M	11.9M	10.7M	7.1M	6.4M
Net Debt	(38.5M)	(67.7M)	(54.3M)	(32.3M)	(33.8M)	(35.5M)
Retained Earnings	(108.5M)	(153.3M)	(197.4M)	(250.5M)	(301.2M)	(286.1M)
Accounts Payable	882.7K	2.1M	2.6M	2.7M	3.5M	1.9M
Cash	44.3M	74.9M	64.4M	51.6M	48.5M	47.6M
Non Current Assets Total	10.6M	12.0M	14.9M	14.1M	10.1M	8.6M
Non Currrent Assets Other	3.4M	3.0M	2.9M	3.2M	2.8M	2.1M
Other Assets	3.4M	3.1M	3.0M	3.4M	3.9M	2.1M
Cash And Short Term Investments	44.3M	84.9M	64.4M	76.3M	48.5M	54.1M
Common Stock Total Equity	26.6K	30.4K	32.2K	43.0K	49.5K	26.3K
Common Stock Shares Outstanding	22.0M	28.7M	31.3M	35.6M	45.8M	30.0M
Short Term Investments	50.1K	18.4M	15.1M	10.0M	0.0	24.7M
Liabilities And Stockholders Equity	71.6M	99.5M	83.4M	91.3M	61.5M	66.4M
Non Current Liabilities Total	5.4M	4.3M	5.1M	14.1M	7.4M	5.1M
Other Current Assets	860.1K	2.5M	1.8M	1.7M	1.2M	1.2M
Other Stockholder Equity	163.1M	232.2M	262.9M	316.2M	338.2M	189.1M
Total Liab	17.0M	20.6M	17.9M	25.6M	24.4M	15.1M
Property Plant And Equipment Gross	7.2M	8.9M	15.4M	14.9M	10.7M	7.7M
Total Current Assets	61.0M	87.5M	68.5M	77.2M	51.5M	57.8M
Accumulated Other Comprehensive Income	(10.3K)	7.1K	0.0	(95.9K)	(110.3K)	(115.8K)
Common Stock	26.6K	30.4K	32.2K	43.0K	47K	29.1K
Property Plant Equipment	7.2M	2.1M	2.1M	1.5M	1.7M	2.6M
Non Current Liabilities Other	5.4M	4.3M	5.1M	6.0M	6.9M	4.8M
Current Deferred Revenue	4.1M	6.7M	645.3K	2.1M	2.4M	3.0M
Net Invested Capital	54.6M	78.9M	65.5M	75.7M	45.3M	65.7M
Net Working Capital	49.4M	71.2M	55.7M	65.6M	34.4M	42.3M
Retained Earnings Total Equity	(108.5M)	(153.3M)	(197.4M)	(250.5M)	(225.4M)	(236.7M)
Capital Surpluse	163.1M	232.2M	262.9M	316.2M	363.6M	237.6M
Capital Stock	26.6K	30.4K	32.2K	43.0K	47K	36.6K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

When determining whether Cue Biopharma is a strong investment it is important to analyze Cue Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Cue Biopharma's future performance. For an informed investment choice regarding Cue Stock, refer to the following important reports:

How To Invest In Cue

Details

Is Cue Stock a good investment?

Details

What is Cue Biopharma's Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Cue Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment.

For information on how to trade Cue Stock refer to our How to Trade Cue Stock guide.

You can also try the Price Transformation module to use Price Transformation models to analyze the depth of different equity instruments across global markets.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cue Biopharma. If investors know Cue will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cue Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.91)

Revenue Per Share

0.172

Quarterly Revenue Growth

0.923

Return On Assets

(0.52)

Return On Equity

(1.39)

The market value of Cue Biopharma is measured differently than its book value, which is the value of Cue that is recorded on the company's balance sheet. Investors also form their own opinion of Cue Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Cue Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cue Biopharma's market value can be influenced by many factors that don't directly affect Cue Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cue Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cue Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cue Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cue Price To Sales Ratio vs Book Value Per Share Analysis

Price To Sales Ratio vs Book Value Per Share

Price To Sales Ratio vs Book Value Per Share Correlation Analysis

Correlation Coefficient

Price To Sales Ratio

Book Value Per Share

Cue Biopharma fundamental ratios Correlations

Cue Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Cue Biopharma fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Non Current Assets Total	+ 1.0	Property Plant And Equipment Net
Common Stock	+ 1.0	Common Stock Total Equity
Total Stockholder Equity	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Stockholder Equity

Cash	- 0.98	Net Debt
Net Debt	- 0.95	Total Stockholder Equity
Common Stock	- 0.94	Retained Earnings
Other Stockholder Equity	- 0.94	Retained Earnings
Total Current Assets	- 0.93	Net Debt
Common Stock Total Equity	- 0.92	Retained Earnings